CETP and atherosclerosis: In conclusion, rimonabant decreases atherosclerosis development in lean hyperlipidemic E3L.CETP mice, as explained by decreased hepatic VLDL particle production and accelerated turnover of VLDL leading to a reduction in plasma non-HDL-C.